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Proteasome inhibition is a novel and promising strategy for the treatment of cancer. Bortezomib is a boronic acid dipeptide that
potently and reversibly inhibits the 26S proteasome. Following intravenous (IV) injection, bortezomib is cleared with a rapid initial
half-life of less than 10 min followed by a longer elimination half-life of 5–15 h. A pharmacodynamic assay has been developed to
measure bortezomib activity at the level of the proteasome. Data from phase I trials show that bortezomib induces predictable, dose-
related, reversible inhibition of proteasome activity. A phase I trial designed to evaluate the safety and pharmacodynamics of
bortezomib administered as a twice-weekly IV bolus for 2 weeks followed by a 1-week rest was conducted in 43 patients with
advanced solid tumours. Dose-limiting toxicities (DLTs) at the dose of 1.56 mg/m2 included diarrhoea and sensory neuropathy. A
partial response was seen in one patient with non-small cell lung cancer. In a second phase I trial, bortezomib was administered twice
weekly for 4 weeks followed by a 2-week rest to 27 patients with refractory haematological malignancies. DLTs included fatigue,
hyponatraemia, and hypokalaemia. Among nine patients with myeloma, there was one complete response and a reduction in
paraprotein level and/or marrow plasmacytosis in the remaining eight. Additionally, two partial responses were seen in patients with
lymphoma. Thus, in phase I testing, bortezomib demonstrated promising clinical activity. It is biologically active and generally well
tolerated. Based on these promising early results, bortezomib is now being actively investigated for the treatment of multiple
myeloma, non-Hodgkin’s lymphoma, and a variety of solid tumours.
 2004 Elsevier Ltd. All rights reserved.
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Proteasome inhibition is a novel and promising
strategy for the treatment of cancer. The ubiquitin–
proteasome pathway is responsible for the degradation
of numerous proteins regulating critical cellular func-
tions such as transcription, cell division, cytokine pro-
duction, and apoptosis [1]. Preclinical studies show that
proteasome inhibitors may be more cytotoxic to tumour
cells than normal cells [1]. In particular, compared with
normal cells, cancer cells appear to be more sensitive to
the pro-apoptotic eﬀects of proteasome inhibition [2]. As
discussed in detail by Dr. Kenneth Anderson [Eur J
Cancer Suppl], proteasome activity is required for acti-
vation of the transcription factor nuclear factor-jB
(NF-jB). Proteasome inhibition prevents the activation* Tel.: +44-208-661-3539; fax: +44-208-661-3541.
E-mail address: stan.kaye@icr.ac.uk (S.B. Kaye).
1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejcsup.2004.04.003of NF-jB by chemotherapy and radiotherapy, resulting
in enhanced sensitivity to these tumouricidal agents and
increased apoptosis in cancer cells in vitro [3].
Bortezomib is a novel boronic acid dipeptide that
potently and selectively inhibits the 26S proteasome.
Importantly – given the fundamental metabolic role
of the ubiquitin–proteasome pathway – bortezomib-
induced inhibition of the proteasome is reversible [4]. In
the National Cancer Institute in vitro screen, bortezo-
mib showed substantial cytotoxicity against a broad
range of human tumour cells [4]. The antitumour eﬀects
of bortezomib have been conﬁrmed in a wide range of
murine xenograft models [2].
Based on this preclinical proﬁle, the early clinical
studies of bortezomib were designed to determine whe-
ther bortezomib induces predictable and dose-depen-
dent proteasome inhibition in patients, to assess the
pharmacodynamic and pharmacokinetic characteristics
of bortezomib, and to identify the toxicities associated
8 S.B. Kaye / EJC Supplements Vol 2 No. 6 (2004) 7–11with bortezomib administration. In addition, the phase I
trials were designed to determine whether bortezomib
demonstrates evidence of antitumour eﬃcacy.2. Pharmacodynamics
In animal models, bortezomib is rapidly removed
from the vascular compartment and distributed widely,
quickly approaching the limits of detection. This sug-
gests that traditional plasma pharmacokinetic parame-
ters would not be appropriate for measuring its activity
[5–7]. A pharmacodynamic assay was therefore devel-
oped to measure and monitor activity at the level of the
proteasome [6]. The method has been shown to be sen-
sitive, speciﬁc, accurate, and precise [6].
In primates treated with twice-weekly injections of
bortezomib for 4 weeks, proteasome activity in white
blood cells was signiﬁcantly decreased at dose levels of
0.54, 0.8, and 1.2 mg/m2, as compared with controls.
Recovery to control activity levels occurred within 72 h.
At the maximum tolerated dose of 0.8 mg/m2, the per-
centage of proteasome inhibition was 76%. Beyond this
level, animals developed hypotension and deaths were
observed [5]. In addition, in animal models continuous
proteasome inhibition produces unacceptable toxicity
(Millennium Pharmaceuticals, Inc. Data on ﬁle).
Fig. 1 shows the pooled clinical data from several
early clinical studies with bortezomib [7]. The curve is
sigmoidal, demonstrating that bortezomib produces a
predictable and dose-related inhibition of proteasome
activity. In these studies, the half-life of bortezomib-
induced proteasome inhibition [(PD)t1=2] varied from
8 to 24 h [7]. Thus, an interval of 72 h between dos-
ing should permit nearly full recovery of proteasome
function [8].Bortezomib Dose (mg/m2)
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Fig. 1. Summary of pharmacodynamic data from phase I trials of
bortezomib. Degree of inhibition of proteasome activity in whole
blood lysate vs. bortezomib dose, 1 h following bortezomib adminis-
tration [7].3. Pharmacokinetics
Following IV injection, bortezomib is cleared with a
very rapid a-half-life of less than 10 min (t1=2a < 10
min), followed by a longer elimination half-life of 5–15 h
(t1=2b 5–15 h). Bortezomib is extensively distributed in
tissues with a large volume of distribution (Vd ¼ 400–
600 L) [9]. In most organs, there is a predictable dose-
related increase in exposure, but bortezomib does not
cross the blood–brain barrier [4].
The major pathway of bortezomib elimination is cy-
tochrome-mediated hepatic metabolism. However, bort-
ezomib is a poor inhibitor of cytochrome P450 in human
microsomes, and there are no speciﬁc recommendations
for dose adjustment with other P450-metabolised medi-
cations. Studies are ongoing to determine the extent
to which bortezomib may safely be administered to
patients with signiﬁcant hepatic dysfunction. The
pharmacokinetic characteristics of bortezomib in pa-
tients with signiﬁcant renal compromise are also being
evaluated.4. Phase I results in patients with solid tumours
A phase I trial was conducted in patients with his-
tologically documented solid tumours refractory to
standard therapy [5]. Eligibility criteria included age
P 18 years; Karnofsky performance status P 70; ade-
quate bone marrow reserve; and adequate hepatic, renal,
and cardiac function. The goals of the study were to
deﬁne the safety, DLTs, and pharmacodynamic behav-
iour of bortezomib administered as a twice-weekly IV
bolus for 2 weeks, followed by a 1-week rest. Tumour
cases included eight patients with non-small cell lung
cancer (NSCLC), six with colon cancer, ﬁve with head
and neck cancer, and four each with melanoma, ovar-
ian, prostate, and renal cancer. Median patient age was
53 years, median Karnofsky performance status was 80,
and patients had received a median of four prior che-
motherapy regimens [5].
Patients received a total of 89 cycles of bortezomib at
doses ranging from 0.13 to 1.56 mg/m2 [5]. No dose-
limiting haematological toxicity was seen at any dose
level [5]. The two DLTs seen at the highest dose level
were diarrhoea and sensory neuropathy. Two of the 12
patients treated with 1.56 mg/m2 developed grade 3 di-
arrhoea. The diarrhoea lasted for 18–36 h after bort-
ezomib dosing and resolved with loperamide treatment
[5]. Diarrhoea on subsequent cycles was successfully
prevented with the use of prophylactic loperamide [5]. In
addition, two other patients treated at the 1.56 mg/m2
dose level experienced grade 3 sensory neuropathy. Both
patients had previously received known neurotoxic
agents (paclitaxel, cisplatin, and carboplatin) and had
preexisting neuropathy at the time of study entry (grade
Fig. 2. Computed tomography of the chest in a patient with bron-
chioloalveolar carcinoma at baseline and following two cycles of
treatment with bortezomib [5].
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The neuropathy improved or resolved in both patients
with cessation of bortezomib treatment [5].
Pharmacodynamically, a clear dose-related inhibition
of proteasome activity was seen at 1 h following IV
administration of bortezomib. Assays performed on
samples drawn immediately before treatment on days 4,
8, and 11 showed recovery of proteasome activity to
baseline. The mean percentages of proteasome inhibi-
tion by dose level were: 31% at 0.4 mg/m2; 42% at 0.6
mg/m2; 48% at 0.75 mg/m2; 57% at 0.9 mg/m2; 46% at
1.08 mg/m2; 65% at 1.3 mg/m2; and 68% at 1.56 mg/m2
[5].
One partial response was documented in a patient
with NSCLC (bronchioloalveolar type). The patient had
progressed on treatment with paclitaxel and carboplatin;
he subsequently progressed on additional treatment with
gemcitabine, mitomycin and vinblastine, docetaxel, and
methotrexate. The patient’s tumour symptoms of cough,
bronchorrhea, and intermittent hemoptysis resolved af-
ter the ﬁrst cycle of bortezomib. As shown in Fig. 2,
chest computerised tomography after two cycles of
therapy showed a 50% reduction in bilateral pulmonary
inﬁltrative masses [5]. The patient stopped bortezomib
treatment after three cycles due to sensory neuropathy.
The duration of response was 3 months. One patient
each with malignant melanoma, nasopharyngeal carci-
noma, and renal cell carcinoma had stable disease as
their best response. The median duration of stable dis-
ease was 4 months [5].5. Phase I results in patients with haematological malig-
nancies
A second phase I trial was conducted in patients with
refractory haematological malignancies [8]. Adult pa-
tients with a pathologically conﬁrmed haematological
malignancy refractory to standard therapy were eligible
for enrollment. Additional eligibility criteria included:(1) Eastern Cooperative Oncology Group (ECOG)
performance status 0–2; (2) expected survival P 6
weeks; (3) adequate cardiovascular and hepatic func-
tion; (4) serum creatinine 6 2.5 mg/dL; and (5) WBC
P 2000/mm3; absolute neutrophil count P 1000/mm3;
haemoglobin P 8.0 g/dL; platelet count P 50,000/mm3.
The objectives of the study were to determine the max-
imum tolerated dose and DLTs of bortezomib admin-
istered to patients with refractory haematological
malignancies as an IV bolus twice weekly for 4 weeks,
followed by a 2-week rest [8].
A total of 27 patients were enrolled and treated at 4
dose levels ranging from 0.40 to 1.38 mg/m2. Diagnoses
included multiple myeloma (11 patients), Waldenstr€om’s
macroglobulinaemia (1), non-Hodgkin’s lymphoma
(10), Hodgkin’s disease (4), and myelodysplasia (1). No
DLTs were observed at the ﬁrst three dose levels of 0.40,
1.04, and 1.20 mg/m2. At the 1.38 mg/m2 dose level, two
of the ﬁve patients experienced DLTs, consisting of
grade 3 hyponatraemia and grade 3 fatigue. Because of
these DLTs, the 1.20 mg/m2 cohort was expanded, but
two of the four additional patients experienced DLTs,
including grade 3 fatigue and grade 3 hypokalaemia.
Enrollment was then continued at the 1.04 mg/m2 dose
level [8].
The most common adverse events overall were
thrombocytopaenia (74% of patients), fatigue (59%),
and nausea (52%). Thrombocytopaenia was the most
common grade 3 event, occurring in 10 patients (37%)
during cycle 1. Patients who entered the study with less
than normal platelet counts were at greatest risk for
thrombocytopaenia. Overall, ﬁve (19%) patients devel-
oped treatment-emergent peripheral neuropathy, con-
sidered bortezomib-related in three cases. All these
patients had received prior therapy with poten-
tially neurotoxic agents, including vinca alkaloids and
thalidomide [8].
Bortezomib induced a dose-dependent inhibition of
proteasome function compared with pretreatment con-
trols. The dose levels of 0.40, 1.04, 1.20, and 1.38 mg/m2
produced inhibitions of 36%, 60%, 65%, and 74%, re-
spectively. As shown in Fig. 3, signiﬁcant proteasome
inhibition was seen within 1 h of dosing, after which the
level of inhibition slowly decayed [8]. The level of inhi-
bition returned toward baseline by 72 h. No cumulative
increase in proteasome inhibition was noted with mul-
tiple cycles of bortezomib treatment, suggesting that the
72-h interval was adequate to allow for recovery of
normal function [8].
Nine of the 12 patients with plasma cell dyscrasias
completed at least one full cycle of therapy and were as-
sessable for response. A complete response was docu-
mented in a patient with IgG-j myeloma treated at the
1.04 mg/m2 dose level. The patient was refractory to
prior treatment with vincristine, doxorubicin, and dexa-
methasone, followed by topotecan and dexamethasone.
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Fig. 3. Bortezomib pharmacodynamics as a function of time. 20S
proteasome inhibition 1, 6, and 24 h after bortezomib administration
in patients treated at 1.04 mg/m2 (n ¼ 12) (means SEM) [8].
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41% plasma cells (Fig. 4(a)) [8]. Pretreatment immuno-
globulins included an IgA of 25 mg/dL (normal 40–390),
IgM of 15 (normal 25–210), and IgG of 3011 (normal
525–1650). Following cycle 1 of bortezomib, bone mar-
row plasmacytosis declined to 1% (Fig. 4(b)) [8]. IgA and
IgM rose to 69 and 44 mg/dL, respectively, and IgG de-
clined to 1215. Immunoﬁxation showed large monoclo-
nal IgG heavy-chain and j-light-chain bands (Fig. 4(c))
[8]. After three cycles of treatment, the immunoﬁxation
took on a polyclonal pattern indicative of a complete
response (Fig. 4(d)) [8]. The patient received four cycles
of bortezomib in total. In follow-up, a faint monoclonal
band reappeared after 6 months, but the patient re-
mained asymptomatic without further antimyeloma
therapy 1 year later. The other eight patients with my-
eloma experienced either a minor response or stable
disease. Partial responses were also observed in one pa-Fig. 4. Response of a patient with IgG myeloma to bortezomib. Pa-
tient’s bone marrow biopsy before therapy (a) and after cycle 1 of
bortezomib (b). Patient’s serum protein electrophoresis (SPE) and
immunoﬁxation for IgG and j-light chains before therapy (c) and after
cycle 3 of bortezomib (d) [8].tient with mantle cell lymphoma and one patient with
refractory follicular lymphoma [8].6. Combined analysis of safety and tolerability
Overall, more than 200 patients have been treated
with bortezomib in phase I trials. In a pooled analysis of
the phase I data, the most commonly reported adverse
events were fatigue and gastrointestinal symptoms, in-
cluding nausea, vomiting, constipation, and diarrhoea
(Millennium Pharmaceuticals, Inc. Data on ﬁle). These
symptoms (more often seen at doses >1.3 mg/m2) were
generally grades 1–2 and led to treatment discontinua-
tion in only 2–3% of cases. Peripheral neuropathy oc-
curred less frequently, but was potentially dose limiting.
The incidence of neuropathy, which tended to occur in
patients who had received prior treatment with neuro-
toxic agents, was also dose-related (Millennium Phar-
maceuticals, Inc. Data on ﬁle).
Based on the phase I results, a dose schedule of
bortezomib twice weekly for 2 weeks followed by a 10-
day rest was recommended for further clinical develop-
ment. The dose of 1.3 mg/m2 given according to this
schedule was selected for the large phase II trial of
bortezomib as a single agent in patients with relapsed
and refractory multiple myeloma (SUMMIT).7. Summary and conclusions
In early clinical trials, the novel proteasome inhibitor
bortezomib shows promising antitumour activity in
patients with both solid tumours and haematological
malignancies. Bortezomib is biologically active, pro-
ducing predictable, dose-related, and reversible protea-
some inhibition. Treatment with bortezomib is generally
well tolerated. The most common adverse eﬀects include
gastrointestinal symptoms and fatigue. Peripheral neu-
ropathy occurs less frequently, mainly in patients with
prior exposure to neurotoxic agents. Side eﬀects are
generally dose-related, mild to moderate in severity, and
reversible upon dose reduction and/or cessation of
bortezomib therapy.
Based on the promising early clinical trial results,
bortezomib is being actively investigated for treatment
of multiple myeloma, non-Hodgkin’s lymphoma, and a
variety of solid tumours. These studies include an eval-
uation of the use of bortezomib in patients with im-
paired renal function, and an analysis of hepatic
impairment is also planned.Conﬂict of interest statement
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